Responses
Regular and young investigator award abstracts
Clinical trials in progress
346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Compose a Response to This Article
Other responses
No responses have been published for this article.
